285 related articles for article (PubMed ID: 15860657)
21. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers.
von Weymarn LB; Chun JA; Hollenberg PF
Carcinogenesis; 2006 Apr; 27(4):782-90. PubMed ID: 16364922
[TBL] [Abstract][Full Text] [Related]
22. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1.
Duescher RJ; Elfarra AA
Arch Biochem Biophys; 1994 Jun; 311(2):342-9. PubMed ID: 8203896
[TBL] [Abstract][Full Text] [Related]
23. CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.
Yamanaka H; Nakajima M; Fukami T; Sakai H; Nakamura A; Katoh M; Takamiya M; Aoki Y; Yokoi T
Drug Metab Dispos; 2005 Dec; 33(12):1811-8. PubMed ID: 16135656
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
[TBL] [Abstract][Full Text] [Related]
25. Effects of watercress consumption on urinary metabolites of nicotine in smokers.
Hecht SS; Carmella SG; Murphy SE
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):907-13. PubMed ID: 10548320
[TBL] [Abstract][Full Text] [Related]
26. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
J Pharmacol Exp Ther; 1996 May; 277(2):1010-5. PubMed ID: 8627511
[TBL] [Abstract][Full Text] [Related]
27. Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.
Murphy SE
Chem Res Toxicol; 2017 Jan; 30(1):410-419. PubMed ID: 28092945
[TBL] [Abstract][Full Text] [Related]
28. Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes.
Wong HL; Zhang X; Zhang QY; Gu J; Ding X; Hecht SS; Murphy SE
Chem Res Toxicol; 2005 Jun; 18(6):913-8. PubMed ID: 15962925
[TBL] [Abstract][Full Text] [Related]
29. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
30. Modified nicotine metabolism in transgenic tobacco plants expressing the human cytochrome P450 2A6 cDNA.
Dueckershoff K; Unger M; Frank A; Gillam EM; Guengerich FP; Warzecha H
FEBS Lett; 2005 Apr; 579(11):2480-4. PubMed ID: 15848192
[TBL] [Abstract][Full Text] [Related]
31. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.
Hukkanen J; Jacob P; Benowitz NL
Clin Pharmacol Ther; 2006 Nov; 80(5):522-30. PubMed ID: 17112808
[TBL] [Abstract][Full Text] [Related]
32. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
33. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
[TBL] [Abstract][Full Text] [Related]
34. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
35. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
36. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
37. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M; Yokoi T
Drug Metab Pharmacokinet; 2005 Aug; 20(4):227-35. PubMed ID: 16141602
[TBL] [Abstract][Full Text] [Related]
38. The role of cytochromes P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung.
Williams DE; Shigenaga MK; Castagnoli N
Drug Metab Dispos; 1990; 18(4):418-28. PubMed ID: 1976062
[TBL] [Abstract][Full Text] [Related]
39. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
Nakajima M; Yamagishi S; Yamamoto H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2000 Jan; 67(1):57-69. PubMed ID: 10668854
[TBL] [Abstract][Full Text] [Related]
40. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine.
Le Gal A; Dréano Y; Lucas D; Berthou F
Toxicol Lett; 2003 Sep; 144(1):77-91. PubMed ID: 12919726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
